Medical News

RSS

MitrAssist receives ISO certification for design and development of mitral valve prosthesis

MitrAssist Medical Ltd., a developer of minimally invasive products for treating heart disease, announced today that it received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses.

4 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

MARIJUANA announces corporate name change to Hemp

MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.

4 Jun 2012

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

ImmunoGen, Inc., a biotechnology company, today announced the presentation of new clinical data for the investigational compound, SAR3419, at the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago, IL.

4 Jun 2012

High levels of antibody molecule linked to increased rates of death from all diseases

Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.

4 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

RMHCSC awards $328,000 in scholarship funds to Southland high school seniors

Today, Ronald McDonald House Charities of Southern California (RMHCSC) awarded $328,000 in scholarship funds to exceptional high school seniors who reside in Los Angeles, Orange, Riverside, San Bernardino and Ventura counties.

4 Jun 2012

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

4 Jun 2012

Variation in microRNAs may explain survival differences in breast cancer

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered a potential explanation for why breast cancer is not experienced the same way with African American and Caucasian patients.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation.

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Scientists propose new theory of the brain activity behind arm movements

Unlike their visual cousins, the neurons that control movement are not a predictable bunch. Scientists working to decode how such neurons convey information to muscles have been stymied when trying to establish a one-to-one relationship between a neuron's behavior and external factors such as muscle activity or movement velocity.

4 Jun 2012

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that the Phase III EMILIA study of trastuzumab emtansine (T-DM1) met its co-primary endpoint of a significant improvement in the time people with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse (progression-free survival, PFS).

4 Jun 2012

Medical News

MitrAssist receives ISO certification for design and development of mitral valve prosthesis

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

MARIJUANA announces corporate name change to Hemp

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

High levels of antibody molecule linked to increased rates of death from all diseases

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

CTI acquires world-wide rights to S*BIO’s pacritinib

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

RMHCSC awards $328,000 in scholarship funds to Southland high school seniors

Results from Puma’s PB272 Phase I combination trial on metastatic HER-2 positive breast cancer

Variation in microRNAs may explain survival differences in breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Cancer patients with annual incomes below $50,000 less likely to participate in clinical trials

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Scientists propose new theory of the brain activity behind arm movements

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Dr. Anthony Grice

Building quality into drug development for safer, faster medicines

Latest News